| UniProt ID | RNF12_HUMAN | |
|---|---|---|
| UniProt AC | Q9NVW2 | |
| Protein Name | E3 ubiquitin-protein ligase RLIM | |
| Gene Name | RLIM | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 624 | |
| Subcellular Localization | Nucleus . | |
| Protein Description | E3 ubiquitin-protein ligase. Acts as a negative coregulator for LIM homeodomain transcription factors by mediating the ubiquitination and subsequent degradation of LIM cofactors LDB1 and LDB2 and by mediating the recruitment the SIN3a/histone deacetylase corepressor complex. Ubiquitination and degradation of LIM cofactors LDB1 and LDB2 allows DNA-bound LIM homeodomain transcription factors to interact with other protein partners such as RLIM. Plays a role in telomere length-mediated growth suppression by mediating the ubiquitination and degradation of TERF1. By targeting ZFP42 for degradation, acts as an activator of random inactivation of X chromosome in the embryo, a stochastic process in which one X chromosome is inactivated to minimize sex-related dosage differences of X-encoded genes in somatic cells of female placental mammals.. | |
| Protein Sequence | MENSDSNDKGSGDQSAAQRRSQMDRLDREEAFYQFVNNLSEEDYRLMRDNNLLGTPGESTEEELLRRLQQIKEGPPPQNSDENRGGDSSDDVSNGDSIIDWLNSVRQTGNTTRSGQRGNQSWRAVSRTNPNSGDFRFSLEINVNRNNGSQNSENENEPSARRSSGENVENNSQRQVENPRSESTSARPSRSERNSTEALTEVPPTRGQRRARSRSPDHRRTRARAERSRSPLHPMSEIPRRSHHSISSQTFEHPLVNETEGSSRTRHHVTLRQQISGPELLSRGLFAASGTRNASQGAGSSDTAASGESTGSGQRPPTIVLDLQVRRVRPGEYRQRDSIASRTRSRSQTPNNTVTYESERGGFRRTFSRSERAGVRTYVSTIRIPIRRILNTGLSETTSVAIQTMLRQIMTGFGELSYFMYSDSDSEPTGSVSNRNMERAESRSGRGGSGGGSSSGSSSSSSSSSSSSSSSSSSSSPSSSSGGESSETSSDLFEGSNEGSSSSGSSGARREGRHRAPVTFDESGSLPFLSLAQFFLLNEDDDDQPRGLTKEQIDNLAMRSFGENDALKTCSVCITEYTEGNKLRKLPCSHEYHVHCIDRWLSENSTCPICRRAVLASGNRESVV | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 1 | Acetylation | -------MENSDSND -------CCCCCCCC | 11.25 | 22814378 | |
| 4 | Phosphorylation | ----MENSDSNDKGS ----CCCCCCCCCCC | 29.16 | 28450419 | |
| 6 | Phosphorylation | --MENSDSNDKGSGD --CCCCCCCCCCCCC | 46.91 | 28450419 | |
| 9 | Ubiquitination | ENSDSNDKGSGDQSA CCCCCCCCCCCCHHH | 60.26 | 33845483 | |
| 21 | Phosphorylation | QSAAQRRSQMDRLDR HHHHHHHHHHHHHHH | 31.85 | - | |
| 33 | Phosphorylation | LDREEAFYQFVNNLS HHHHHHHHHHHHCCC | 14.21 | 29523821 | |
| 40 | Phosphorylation | YQFVNNLSEEDYRLM HHHHHCCCHHHHHHH | 40.85 | 29523821 | |
| 44 | Phosphorylation | NNLSEEDYRLMRDNN HCCCHHHHHHHHHCC | 14.66 | 29523821 | |
| 72 | Ubiquitination | LRRLQQIKEGPPPQN HHHHHHHHCCCCCCC | 52.89 | 21906983 | |
| 117 | Methylation | NTTRSGQRGNQSWRA CCCCCCCCCCCCEEE | 49.94 | 115491373 | |
| 132 | Phosphorylation | VSRTNPNSGDFRFSL EECCCCCCCCEEEEE | 40.78 | - | |
| 163 | Phosphorylation | NEPSARRSSGENVEN CCCCHHHCCCCCCCC | 36.82 | 28985074 | |
| 164 | Phosphorylation | EPSARRSSGENVENN CCCHHHCCCCCCCCC | 48.60 | 30576142 | |
| 172 | Phosphorylation | GENVENNSQRQVENP CCCCCCCCCCCCCCC | 38.02 | 28102081 | |
| 181 | Phosphorylation | RQVENPRSESTSARP CCCCCCCCCCCCCCC | 36.84 | 22817900 | |
| 183 | Phosphorylation | VENPRSESTSARPSR CCCCCCCCCCCCCCC | 28.98 | 29523821 | |
| 184 | Phosphorylation | ENPRSESTSARPSRS CCCCCCCCCCCCCCC | 23.50 | 29523821 | |
| 185 | Phosphorylation | NPRSESTSARPSRSE CCCCCCCCCCCCCCC | 31.40 | 22817900 | |
| 189 | Phosphorylation | ESTSARPSRSERNST CCCCCCCCCCCCCCC | 42.77 | 29523821 | |
| 191 | Phosphorylation | TSARPSRSERNSTEA CCCCCCCCCCCCCHH | 45.29 | 28450419 | |
| 195 | Phosphorylation | PSRSERNSTEALTEV CCCCCCCCCHHHHCC | 33.57 | 28450419 | |
| 196 | Phosphorylation | SRSERNSTEALTEVP CCCCCCCCHHHHCCC | 28.91 | 28450419 | |
| 200 | Phosphorylation | RNSTEALTEVPPTRG CCCCHHHHCCCCCCC | 41.82 | 28450419 | |
| 213 | Phosphorylation | RGQRRARSRSPDHRR CCCCCHHHCCCCHHH | 35.80 | 30576142 | |
| 215 | Phosphorylation | QRRARSRSPDHRRTR CCCHHHCCCCHHHHH | 35.61 | 30576142 | |
| 228 | Phosphorylation | TRARAERSRSPLHPM HHHHHHHHCCCCCCC | 28.72 | 23927012 | |
| 230 | Phosphorylation | ARAERSRSPLHPMSE HHHHHHCCCCCCCCC | 32.81 | 23927012 | |
| 236 | Phosphorylation | RSPLHPMSEIPRRSH CCCCCCCCCCCCCCC | 36.50 | 23927012 | |
| 276 | Phosphorylation | VTLRQQISGPELLSR EEHHHHCCCHHHHHC | 43.91 | 25787250 | |
| 282 | Phosphorylation | ISGPELLSRGLFAAS CCCHHHHHCCEEEEC | 36.61 | 23312004 | |
| 295 | Phosphorylation | ASGTRNASQGAGSSD ECCCCCCCCCCCCCC | 32.47 | - | |
| 347 | Phosphorylation | ASRTRSRSQTPNNTV HHCCCCCCCCCCCEE | 39.39 | - | |
| 349 | Phosphorylation | RTRSRSQTPNNTVTY CCCCCCCCCCCEEEE | 29.27 | 28985074 | |
| 360 | Methylation | TVTYESERGGFRRTF EEEEEECCCCEEEEE | 60.87 | 26494409 | |
| 364 | Methylation | ESERGGFRRTFSRSE EECCCCEEEEECHHH | 39.75 | 30989225 | |
| 459 | Phosphorylation | GSSSGSSSSSSSSSS CCCCCCCCCCCCCCC | 35.62 | - | |
| 460 | Phosphorylation | SSSGSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 461 | Phosphorylation | SSGSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 462 | Phosphorylation | SGSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 463 | Phosphorylation | GSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 464 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 465 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 466 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 467 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 468 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 469 | Phosphorylation | SSSSSSSSSSSSSSS CCCCCCCCCCCCCCC | 35.87 | - | |
| 470 | Phosphorylation | SSSSSSSSSSSSSSP CCCCCCCCCCCCCCC | 35.87 | - | |
| 471 | Phosphorylation | SSSSSSSSSSSSSPS CCCCCCCCCCCCCCC | 35.87 | - | |
| 472 | Phosphorylation | SSSSSSSSSSSSPSS CCCCCCCCCCCCCCC | 35.87 | 24275569 | |
| 503 | Phosphorylation | SNEGSSSSGSSGARR CCCCCCCCCCCCCCC | 44.64 | - | |
| 505 | Phosphorylation | EGSSSSGSSGARREG CCCCCCCCCCCCCCC | 27.78 | - | |
| 506 | Phosphorylation | GSSSSGSSGARREGR CCCCCCCCCCCCCCC | 39.74 | - | |
| 550 | Ubiquitination | DQPRGLTKEQIDNLA CCCCCCCHHHHHHHH | 53.30 | 21963094 | |
| 558 | Sulfoxidation | EQIDNLAMRSFGEND HHHHHHHHHHHCCCC | 4.09 | 21406390 | |
| 568 | Ubiquitination | FGENDALKTCSVCIT HCCCCHHHHCCEEEE | 49.56 | 29967540 | |
| 582 | Ubiquitination | TEYTEGNKLRKLPCS EECCCCCCEEECCCC | 61.60 | 22505724 | |
| 585 | Ubiquitination | TEGNKLRKLPCSHEY CCCCCEEECCCCCEE | 68.19 | - |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RNF12_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RNF12_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| RNF12_HUMAN | RLIM | physical | 19117995 | |
| ESR1_HUMAN | ESR1 | physical | 19117995 | |
| PDLI1_HUMAN | PDLIM1 | physical | 19117995 | |
| LDB1_HUMAN | LDB1 | physical | 20423330 | |
| REXO1_HUMAN | REXO1 | physical | 22596162 | |
| SMUF2_HUMAN | SMURF2 | physical | 21945933 | |
| TERF1_HUMAN | TERF1 | physical | 19164295 | |
| UB2D1_HUMAN | UBE2D1 | physical | 22596162 | |
| UB2D1_HUMAN | UBE2D1 | physical | 19164295 | |
| LNX2_HUMAN | LNX2 | physical | 22493164 | |
| RS14_HUMAN | RPS14 | physical | 21988832 | |
| SNX17_HUMAN | SNX17 | physical | 21988832 | |
| STMN1_HUMAN | STMN1 | physical | 24686088 | |
| STMN1_HUMAN | STMN1 | physical | 26317901 | |
| MDM2_HUMAN | MDM2 | physical | 26926424 | |
| UB2D1_HUMAN | UBE2D1 | physical | 26926424 | |
| REN3B_HUMAN | UPF3B | physical | 28514442 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...